Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

iprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Commonly observed adverse events (greater than or equal to 5% incidence and at a rate at least twice the rate of placebo for aripiprazole vs placebo, respectively):

     Aripiprazole Oral

     In 3-week bipolar mania trials the following were reported: akathisia

     (15% vs 3%), constipation (13% vs 6%), sedation (8% vs 3%), tremor (7% vs

     3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% vs 2%).

     In 4- to 6-week schizophrenia trials the following was reported:

     akathisia (8% vs 4%).

     A similar adverse event profile was observed in a 26-week trial in

     schizophrenia except for a higher incidence of tremor (aripiprazole 8% vs

     placebo 2%).


     Aripiprazole Injection

     In short-term (24 hour) trials in patients with agitation associated with

     schizophrenia or bipolar mania the following was reported: nausea (9% vs

     3%).


    Treatment-emergent adverse events reported with:


     Aripiprazole Oral

     In short-term trials of patients with schizophrenia (up to 6 weeks) or

     bipolar disorder (up to 3 weeks), the following were reported at an

     incidence greater than or equal to 10% and greater than placebo,

     respectively: headache (30% vs 25%), anxiety (20% vs 17%), insomnia (19%

     vs 14%), nausea (16% vs 12%), vomiting (12% vs 6%), dizziness (11% vs

     8%), constipation (11% vs 7%), dyspepsia (10% vs 8%), and akathisia (10%

     vs 4%).


     Aripiprazole Injection

     In short-term (24 hour) trials, the following were reported at an

     incidence greater than or equal to 5% and greater than placebo,

     respectively: headache (12% vs 7%), nausea (9% vs 3%), dizz
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:6/30/2015)... 2015 Olympus, a global technology leader ... and surgical procedures, among other core businesses, announced ... equipment at no additional charge. Olympus is the ... of guarantee. The service became available to customers ... year. Olympus, Full Service Agreement ...
(Date:6/30/2015)... , June 30, 2015 First Choice Wellness ... the Astanza Duality and is the only clinic in ... professional tattoo removal treatments. The practice has recently expanded ... brand to showcase their focus in the procedure. ... better results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical Company focused on the development of oral ... has been screened in the Company,s Phase IIb trial ... study will be performed under the active Investigational New ... and Drug Administration (FDA). The Phase IIb ...
Breaking Medicine Technology:Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... July 21, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced that it will report ... 2011 after the U.S. market closes on August 8, 2011. ... AM on August 9, 2011 U.S. Eastern Time (8:00 PM ...
... advances impacting both individual lives and public health in ... announced the 2011 final candidates for the 5th annual ... the technical, scientific and clinical research skills necessary to ... industry,s highest accolade. Final candidates for the ...
Cached Medicine Technology:Mindray to Report Second Quarter 2011 Financial Results on August 8, 2011 22011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent 2
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
(Date:6/30/2015)... NJ (PRWEB) , ... June 30, 2015 , ... Dr. ... primary care sports medicine physician. He specializes in the diagnosis and treatment of non-surgical ... and for the people who participate in recreational athletics and use exercise to stay ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates today ... Healthcare Research & Analytics , a consultative healthcare market research practice that is ... businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research services ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... partnering to improve access to cancer prevention, screening and care for the people ... announced an affiliation that will see Roswell Park faculty providing clinical consultations to ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... New Energy ... York July 7th and 11th 2015. Timber frame post and beam raisings offer a ... , “Raising a timber frame is an important and exciting event – ...
Breaking Medicine News(10 mins):Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4
... French . , MONTREAL, December 14, 2010 The first ... to recognize the sound of their parents, voice and the parents ... and newborns admitted to the intensive care unit can be very ... Jan Lariviere, a nurse in the neonatal clinic and the Neonatal ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most ... United States is funded by states, not the federal government, ... variation in the extent to which states prioritized human embryonic ... in states could likely have been funded under federal government ...
... a woman in New Hampshire have received the first kidney ... Organ Procurement and Transplantation Network (OPTN) that uses a Carnegie ... donors. Both recipients Ken Crowder of St. Louis and ... were willing to donate a kidney but who were medically ...
... (HealthDay News) -- A federal judge ruled Monday that the ... government has no authority to require citizens to buy health ... new legislation, signed into law in March by President Barack ... supporters and opponents of the legislation anticipate the validity of ...
... that alter the activity of genes direct changes to ... control when genes are switched on and off, called epigenetic ... an opening for the cancerous growth of cells. Researchers ... at work on a genome-wide scale in cases of ovarian ...
... HealthDay Reporter , MONDAY, Dec. 13 (HealthDay News) ... may be child,s play, researchers report. A new ... cereals if they,re given a selection of choices at breakfast, ... fruit instead. The 5-to-12-year-olds in the study still ate ...
Cached Medicine News:Health News:Once upon a time in the Intensive Care Unit ... 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Ovarian cancer advances when genes are silenced 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 3
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: